Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Genmab A (GNMSF) Short-term Investments (2023 - 2025)

Historic Short-term Investments for Genmab A (GNMSF) over the last 3 years, with Q3 2025 value amounting to $140.0 million.

  • Genmab A's Short-term Investments rose 22558.14% to $140.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $140.0 million, marking a year-over-year increase of 22558.14%. This contributed to the annual value of $11.0 million for FY2024, which is 9450.0% down from last year.
  • According to the latest figures from Q3 2025, Genmab A's Short-term Investments is $140.0 million, which was up 22558.14% from $122.0 million recorded in Q2 2025.
  • Genmab A's Short-term Investments' 5-year high stood at $200.0 million during Q4 2023, with a 5-year trough of $2.0 million in Q2 2024.
  • Over the past 3 years, Genmab A's median Short-term Investments value was $101.0 million (recorded in 2025), while the average stood at $91.0 million.
  • Its Short-term Investments has fluctuated over the past 5 years, first tumbled by 9450.0% in 2024, then soared by 600000.0% in 2025.
  • Over the past 3 years, Genmab A's Short-term Investments (Quarter) stood at $200.0 million in 2023, then crashed by 94.5% to $11.0 million in 2024, then surged by 1172.73% to $140.0 million in 2025.
  • Its last three reported values are $140.0 million in Q3 2025, $122.0 million for Q2 2025, and $80.0 million during Q1 2025.